TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01560884
Drug: Renazorb 4500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
Study: NCT01560884
Drug: Renazorb 6000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
Study: NCT00869661
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg bid for 24 weeks
Study: NCT00869661
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg bid for 12 weeks
Study: NCT00869661
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg bid for 8 weeks
Study: NCT00869661
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg bid for 12 weeks
Study: NCT01908205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00640458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01845116
Drug: Omegaven®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
Study: NCT01355302
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Study: NCT01712451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02091310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02091310
Drug: GFT505
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00490854
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific, inhaled, at meals, 76 weeks
Study: NCT04087317
Drug: Paracetamol 1000 Mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Study: NCT04087317
Drug: Ibuprofen 400Mg Tab
Normalized name: IBUPROFEN 400MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
Study: NCT04087317
Drug: Paracetamol 1000 Mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Study: NCT04087317
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
Study: NCT04087317
Drug: MIR
Normalized name: Miraa
Approvals — FDA: no, EMA: no, PMDA: no
Description: At any time, if a woman experienced pain despite the prescribed treatment, the next line of treatment was MIR (morphine immediate release, 10 mg tablet).
Study: NCT04385095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via inhalation
Study: NCT01283646
Drug: Apevitin BC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 to 5 ml 3 times a daily
Study: NCT00004988
Drug: VNP20009
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00436917
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid
Study: NCT00808509
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At least 10 mg/week administered orally or subcutaneously
Study: NCT00587431
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
Study: NCT00196820
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02169791
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
Study: NCT00291473
Drug: CHP-HER2, CHP-NY-ESO-1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02466386
Drug: SPD489
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
Study: NCT01966809
Drug: Photofrin photodynamic therapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery.
Study: NCT00779220
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00779220
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral repeating dose
Study: NCT01083238
Drug: AZD5069
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg single oral dose
Study: NCT00980408
Drug: Glutamic Acid
Normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg, one dose, 60 minutes prior
Study: NCT00136760
Drug: Contingent reinforcement plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: contingent reinforcement plus placebo (3 weeks)
Study: NCT00136760
Drug: Non-contingent reinforcement plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-contingent reinforcement plus placebo
Study: NCT01634412
Drug: SL TNX-102 2.4 mg at pH 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
Study: NCT01634412
Drug: SL TNX-102 2.4 mg at pH 7.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
Study: NCT00159536
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
Study: NCT02635035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
Study: NCT00869440
Drug: CNS 7056
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a single intravenous injection by a syringe driver over 1 minute
Study: NCT04314843
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT02111122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004344
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00267163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02586363
Drug: Baraclude Tab. 0.5mg, fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study: NCT02586363
Drug: Cavir Tab. 0.5mg, fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study: NCT02586363
Drug: Cavir Tab. 0.5mg, high fatty meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
Study: NCT01886937
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
Study: NCT01795235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT03649698
Drug: Placebo protein powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric maltodextrin powder. Amount based on food diary.
Study: NCT03649698
Drug: Placebo omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
Study: NCT00039910
Drug: (PN-152,243)/ PN-196,444
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00537017
Drug: Other Parkinson's Disease treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
Study: NCT00145613
Drug: Systemic chemotherapy and antibodies
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
Study: NCT00406016
Drug: ATI355
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as for Growth hormone group
Study: NCT01923311
Drug: Background regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
Study: NCT04119557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04119557
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00772616
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: closed-loop administration using bispectral index as the single input for the controller.
Study: NCT00772616
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage according to usual criteria
Study: NCT00757679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00578968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
Study: NCT00332124
Drug: Choline
Normalized name: Choline
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900 mg every day until birth of infant
Study: NCT02234089
Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to medical practice
Study: NCT03471988
Drug: AK1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557
Study: NCT03081728
Drug: IV diclofenac and IV paracetamol
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
Study: NCT01636934
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
Study: NCT00159835
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02733627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02688387
Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
Study: NCT03055741
Drug: DHP1401
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
Study: NCT03055741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administrated in two divided dosed a day for 24 weeks
Study: NCT02448420
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
Study: NCT02448420
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
Study: NCT02959944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules administered orally daily
Study: NCT00546910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules of placebo have to be taken once daily in the morning, with or without food.
Study: NCT03164109
Drug: GC4419 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg infused IV over 15 minutes
Study: NCT03164109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infused IV over 15 minutes
Study: NCT00399893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered by subcutaneous injection three times daily while on study
Study: NCT04412057
Drug: CERC-002
Normalized name: CERCIS SILIQUASTRUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg.
Study: NCT04412057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once subcutaneously
Study: NCT01529268
Drug: DR cysteamine bitartrate capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~* 750 mg/day (five 75 mg capsules twice daily) for patients \>65 - 80 kg at baseline~* 900 mg/day (six 75 mg capsules twice daily) for patients \>80 kg at baseline
Study: NCT01158326
Drug: Resfenol
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours.
Study: NCT03747653
Drug: FRSW107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered a single dose of FRSW107 for Injection.
Study: NCT02801435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for twice daily
Study: NCT00493064
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical eye drops
Study: NCT02037282
Drug: Anti-influenza IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06267794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg dosage. Additionally, all participating subjects will receive standard treatment care for patients with cirrhosis.
Study: NCT04082806
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
Study: NCT03446599
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
Study: NCT02833207
Drug: Drug Trial 1 (EDD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Study: NCT02833207
Drug: Drug Trial 2 (ROV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description.
Study: NCT03355196
Drug: LRX712
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single dose on Day 1
Study: NCT02135198
Drug: 2 mg AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 2 mg oral dose of AZD7325
Study: NCT02135198
Drug: 10 mg AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 10 mg oral dose of AZD7325
Study: NCT03355196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single dose on Day 1
Study: NCT02135198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose
Study: NCT00504933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (encapsulated) Tablets QD/14 days
Study: NCT01098110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matching placebo of asenapine sublingual tablet not containing asenapine
Study: NCT02147587
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily with background methotrexate for 12 weeks
Study: NCT02184741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
Study: NCT02330952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/day per os for 5 days
Study: NCT02270749
Drug: FitForMe vitamin B12
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
Study: NCT02786927
Drug: Placebo ELLIPTA device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
Study: NCT02786927
Drug: Placebo capsules for use in HANDIHALER device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
Study: NCT00974454
Drug: Fuzheng 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT03749733
Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed Drug
Study: NCT03749733
Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT03327350
Drug: Oral anticoagulant drugs
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
Study: NCT03019562
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
Study: NCT00974454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Study: NCT01350596
Drug: Alivium®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
Study: NCT01350596
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
Study: NCT00914212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo to sibutramine in two of three treatment periods.
Study: NCT03879122
Drug: ADT (androgen deprivation therapy)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy per the standard of care
Study: NCT01923220
Drug: HO/02/02 20µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily